LONDON, January 23, 2012 /PRNewswire/ --
Roche sets up co -marketing agreement with private laboratory to support greater access to HPV testing
In an innovative commercial agreement, leading healthcare company Roche and foremost private cellular pathology laboratory Unilabs-IHS, are collaborating to help make state-of-the art testing for signs of cervical cancer more accessible to thousands of women in London and throughout the UK.
Roche's leading-edge and fully automated cobas® HPV test which runs on the acclaimed cobas 4800 system, will provide a fast turn-around of cervical smear samples from potentially thousands of women per year, sent to the London based laboratory from clinicians from all over the country. The testing at Unilabs-IHS, will not only be conducted as a follow up to the traditional "Pap" cervical smear method to check ambiguous results, it will also be used upon request in primary screening for cervical pre cancer, giving a greater chance to avoid disease progression.
The ultra-high reliability of the cobas HPV test will be of huge benefit for clinicians and patients alike, due to the test's unique genotyping that individually identifies genotypes 16 and 18, the highest risk types associated with the development of cervical cancer and its precursor lesions, while simultaneously identifying 12 other high risk HPV types. Such technology provides better risk stratification of patients enabling a more sensitive and efficient approach to cervical screening.
Dr Glen Dixon, Medical Director of Cytopathology at Unilabs-IHS from Unilabs-IHS said "We are delighted to have come to this agreement with Roche. Using the cobas HPV test on the cobas 4800 platform for our HPV testing work load, means that clinicians will not only have the fastest ever turnaround times, but will also have enhanced and incontrovertible HPV results, with no n
Copyright©2010 PR Newswire.
All rights reserved